Weight management methods and compositions
Combining PDE4 inhibitors like roflumilast with neurotransmitter reuptake inhibitors like bupropion provides a safe and effective treatment for obesity and compulsive eating disorders, achieving weight loss and managing related health issues.
Patent Information
- Application Number
- PCT/US2026/027476
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-09
- Filing Date
- 2026-05-09
- Publication Date
- 2026-11-12
AI Technical Summary
Current treatments for obesity and compulsive eating disorders, such as binge-eating disorder, are often ineffective, unsafe, or expensive, and there is a need for safe and effective methods to manage weight and associated comorbidities.
Administering a combination of a phosphodiesterase IV (PDE4) inhibitor, such as roflumilast, and a neurotransmitter reuptake inhibitor, such as bupropion, to reduce food intake and treat obesity and compulsive eating disorders, with potential benefits for weight management and related comorbidities.
The combination of roflumilast and bupropion effectively reduces food intake and body weight, addressing obesity and compulsive eating disorders, while also managing associated conditions like hypertension, diabetes, and cardiovascular diseases.
Smart Images

Figure 00000032_0000
Abstract
Description
[0001] WEIGHT MANAGEMENT METHODS AND COMPOSITIONS
[0002] RELATED APPLICATIONS
[0003] This application claims the benefit of the filing date of U.S. Provisional Application No.
[0004] 63 / 803,421 which was filed on May 9, 2025. For the purpose of any U.S. application or patent that claims the benefit of U.S. Provisional Application No. 63 / 803,421,
[0005] the content of that earlier filed application is hereby incorporated by reference in its entirety.
[0006] BACKGROUND OF THE INVENTION
[0007] 1. Obesity is a multifactorial disease that is influenced by multiple genetic, behavioral, and environmental factors. Different strategies are employed for treating obesity and / or weight related disorders and may include dietary restriction, increased physical activity, pharmacological methods, and surgical approaches. Treatment options vary depending, at least in part, on the degree of weight loss one is attempting to achieve, the severity of obesity exhibited by the subject, existing comorbidities, and the side effects associated with a particular treatment. Treatments such as low-fat diet and / or regular exercise are often adequate in cases where a subject is only slightly overweight, but may be less effective for morbidly obese subjects. Alternatively, weight management approaches that include medications may be useful in such subjects, although many pharmacological treatments are often limited in utility because they are expensive, ineffective, or unsafe.
[0008] 2. While most individuals who have compulsive eating disorders such as binge eating disorder are overweight or obese, some subjects may be normal weight. Binge-eating disorder is often accompanied by eating rapidly over a short period of time, eating when the subject is not hungry and is uncomfortably full, or uncontrolled eating that can affect the subject's feelings or behavior.
[0009] Behavioral therapy, cognitive therapy and nutrient counseling are often used as starting points to treat compulsive eating disorders such as binge-eating disorders. Initial treatment of compulsive eating disorders such as binge eating disorder is challenging and may be unsuccessful, thus requiring follow-up treatment with medication. There is a continuing need for safe and effective treatments for obesity, compulsive eating disorders such as binge-eating disorders, and related comorbidities and complications.SUMMARY OF THE INVENTION
[0010] 3. Provided herein are methods of treating a subject suffering from overweight or obesity. The methods include administering to the subject a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof. Also provided are methods of treating a subject suffering from a compulsive eating disorder or who is at risk for a compulsive eating disorder. The methods include administering to the subject a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof. In some embodiments, phosphodiesterase IV (PDE4) inhibitor can be roflumilast. In some embodiments the neurotransmitter reuptake inhibitor can be bupropion. The compositions can be administered before or after treatment with an agent promoting weight loss or an agent for treatment of neurological disorders. The subject can be human or an animal, such as a companion animal.
[0011] 4. Some embodiments disclosed herein are related to a method of treating an obese or overweight subject for weight management, comprising treating the subject by administering a phosphodiesterase IV (PDE4) inhibitor, such as roflumilast and its analogues, combined with a neurotransmitter reuptake inhibitor, such as bupropion and its analogues wherein said treatment is useful for the treatment of weight-related disorders.
[0012] 5. Some embodiments disclosed herein are related to a method of treating a subject with a compulsive eating disorder such as binge- eating disorder, comprising treating the subject by administering a phosphodiesterase IV (PDE4) inhibitor, such as roflumilast and its analogues, combined with neurotransmitter reuptake inhibitor, such as bupropion and its analogues, wherein said treatment reduces food intake and is useful for the treatment of a compulsive eating disorder such as binge-eating disorder.Some embodiments disclosed herein are related to the said treatment of an obese or overweight subject in accordance with current regulatory or government treatment guidelines, such as FDA Guidance for Industry Developing Products for Weight Management, wherein said treatment is useful for the treatment of excess body weight.
[0013] 6. Some embodiments disclosed herein are related to the said treatment being given to an overweight or obese subject that is at increased risk of major adverse cardiovascular outcomes wherein said treatment is useful for the treatment of cardiovascular disease.7. Some embodiments disclosed herein are related to the said treatment being useful for the treatment of an overweight or obese subject that is at increased risk of weight-related comorbidities and the said treatment is useful for treating one or more weight-related comorbidities, such as hypertension, type 2 diabetes mellitus, dyslipidemia, nonalcoholic fatty liver disease, NASH, atherosclerosis, or micro- or macro-vascular disease.
[0014] 8. Some embodiments disclosed herein are related to the said treatment being useful for the treatment of one or more weight-related dyslipidemia disorders, such hypertriglyceridemia and hypercholesterolemia, in said overweight or obese subject.
[0015] 9. Some embodiments disclosed herein are related to the said treatment being useful for the treatment of one or more weight-related kidney disorders, such as gout, acute kidney disease, or chronic kidney disease.
[0016] 10. Some embodiments disclosed herein are related to the said treatment being useful for treating one or more weight-related glycemic disorders, such as type 2 diabetes mellitus, prediabetes, or diabetes related complications.
[0017] 11. Some embodiments disclosed herein are related to the said treatment being useful for the treatment of one or more weight-related liver disorders such as nonalcoholic fatty liver disease, or nonalcoholic steatohepatitis in said overweight or obese subject.
[0018] 12. Some embodiments disclosed herein wherein the said overweight or obese subject is administered at least a single daily dose of a phosphodiesterase 4C (PDE4C) inhibitor and at least a single daily dose of an organic cation transport (OCT2, SLC22A2) inhibitor.
[0019] 13. Some embodiments disclosed herein wherein the PDE4 inhibitor is roflumilast, apremilast, cilomilast, tetomilast, lirimilast, ibudilast, tofimilast, filaminast, piclamilast, crisaborole, rolipram, theophylline, doxofylline, denbufylline, enprofylline, arofylline, cipamfylline, drotaverine, Gsk256066, E6005, MK-0873, (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2- phenylethyl]pyridine, mesopram, N-(3,5-dichloro-4-pyridinyl)-2-[l-(4-fluorobenzyl)-5-hydroxy- lH-indol-3-yl]-2-oxoacetamide, CDC-801, CC-1088, CC-11050, ONO-6126, CC-10004 or MN-001, optionally in the form of their racemates, their enantiomers, their diastereomers, their active metabolites, and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts and optionally their pharmacologically-active metabolites.
[0020] 14. Some embodiments disclosed herein wherein the neurotransmitter reuptake inhibitor isbupropion, sibutramine, diethylpropion, mazindol, tesofensine, lisdexamfetamine optionally in the form of their racemates, their enantiomers, their diastereomers, their active metabolites, and mixtures thereof, and optionally their pharmacologically compatible acid addition salts and optionally their pharmacologically active metabolites.
[0021] 15. Some embodiments disclosed herein wherein the said overweight or obese subject is administered at least a single daily dose of 0.25 mg of roflumilast, or a pharmaceutically acceptable saltthereof and simultaneously given at least a single daily dose of 75 mg bupropion, or a pharmaceutically acceptable salt thereof.
[0022] 16. Some embodiments disclosed herein wherein the said overweight or obese subject is first given at least a single daily dose of bupropion alone for at least 3 days prior to be treated with both bupropion and roflumilast.
[0023] 17. Some embodiments disclosed herein wherein the said overweight or obese subject is first given at least a single daily dose of roflumilast alone for at least 4 weeks prior to be treated with both bupropion and roflumilast.
[0024] 18. Some embodiments disclosed herein wherein the subject is administered at least a single daily dose of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of 75 mg of bupropion or a pharmaceutically acceptable salt thereof daily for a period of at least four weeks; and subsequently increasing the treatment dose of the overweight or obese subject by administering to the subject a total daily dose not to exceed 0.5 mg of roflumilast, or a pharmaceutically acceptable salt thereof and administering to the subject a total daily dose not to exceed 450 mg of bupropion, or a pharmaceutically acceptable salt thereof for a period of at least 12 weeks.
[0025] 19. Some embodiments disclosed herein wherein the subject is administered at least a total daily dose of 0.5 mg of roflumilast, or a pharmaceutically acceptable salt thereof and at least a total daily dose of 100 mg bupropion, or a pharmaceutically acceptable salt thereof for a period of atleast 12 weeks to achieve weight loss; and subsequently reducing the total dose of either or both roflumilast or bupropion to reduce weight loss or improve tolerability.
[0026] 20. Some embodiments disclosed herein wherein the subject is administered about 0.25 mg of roflumilast or a pharmaceutically acceptable salt thereof and at least 75 mg bupropion or a pharmaceutically acceptable salt thereof daily for four weeks of treatment; and subsequently treating the overweight or obese subject by administering to the subject at least a once daily dose of 0.5 mgof roflumilast, or a pharmaceutically acceptable salt thereof and at least a once daily dose of at least 100 mg of extended or sustained release bupropion, or a pharmaceutically acceptable salt thereof for a period of at least 12 weeks.
[0027] 21. Some embodiments disclosed herein wherein the subject is administered at least a once daily dose of 0.5 mg of roflumilast, or a pharmaceutically acceptable salt thereof and at least a once daily dose of at least 100 mg of extended or sustained release bupropion, or a pharmaceutically acceptable salt thereof for a period of at least 12 weeks to achieve weight loss; and subsequently reducing the dose to maintain body weight by administering to the subject a single daily dose of east 0.25 mg of roflumilast, or a pharmaceutically acceptable salt thereof and a single daily dose of at least 75 mg bupropion, or a pharmaceutically acceptable salt thereof for a period of at least 12 weeks.
[0028] 22. Some embodiments disclosed herein wherein the treatment includes roflumilast, bupropion and excipients in the form of an oral capsule or tablet.
[0029] 23. Some embodiments disclosed herein wherein the excipients consist of magnesium stearate, lactose monohydrate, cornstarch, polyvinylpyrrolidone (povidone), glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl alcohol, polyethylene glycol, silicon dioxide, triethyl citrate, magnesium silicate, titanium dioxide, carnauba wax, cysteine hydrochloride, polysorbate 80, and mixtures thereof, and optionally pharmacologically related excipients.
[0030] 24. Some embodiments disclosed herein wherein the excipients consist of Natrosol hydroxyethyl cellulose and mixtures thereof, and optionally pharmacologically related excipients, including but not limited to ethylcellulose, hydroxypropyl cellulose, hypromelloses, microcrystalline cellulose.
[0031] 25. Some embodiments disclosed herein wherein the subject is administered at least a single daily dose of roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of bupropion or a pharmaceutically acceptable salt thereof; and subsequently treating theoverweight or obese subject by co-administering to the subject an additional agent, for example, a third agent promoting weight loss.
[0032] 26. Some embodiments disclosed herein wherein the subject is administered at least a single daily dose of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of 75 mg bupropion or a pharmaceutically acceptable salt thereof; and treating the overweight or obese subject by co-administering to the subject a single daily dose of an agent inhibiting glucose absorption, such as a SGLT sodium glucose transporter inhibitor, such as empagliflozin, or alpha-glucosidase inhibitor, such as acarbose.
[0033] 27. Some embodiments disclosed herein wherein the subject is administered at least a single daily dose of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of 75 mg bupropion or a pharmaceutically acceptable salt thereof; and treating the overweight or obese subject by co-administering to the subject a single daily dose of an agent targeting the GLP1 receptor, such as semaglutide, liraglutide, danuglipron, or a dual GIP / GLP-1 receptor co-agonist, such as tirzepatide, or a dual amylin / GLP-1 receptor co-agonist such as amycretin.
[0034] 28. Some embodiments disclosed herein wherein the subject is administered at least a single daily dose of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of 75 mg bupropion or a pharmaceutically acceptable salt thereof; and treating the overweight or obese subject by co-administering to the subject a weight loss agent inhibiting lipid absorption, such as the pancreatic lipase inhibitor, orlistat, or the microsomal transfer protein inhibitor, lomitapide.
[0035] 29. Some embodiments disclosed herein wherein the subject is first administered a therapeutic agent promoting weight loss, including but not limited to agents targeting the GLP1 receptor, sodium glucose transporter (SGLT), pancreatic lipase and / or the microsomal transfer protein for at least 12 weeks, followed by a body weight maintenance dose consisting of at least a single daily dose of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and at least a single daily dose of 75 mg bupropion or a pharmaceutically acceptable salt.
[0036] 30. Some embodiments disclosed herein wherein the subject is administered a daily dose of no less than 0.1 mg of roflumilast or a pharmaceutically acceptable salt thereof, and no less than 30 mg bupropion, or a pharmaceutically acceptable salt thereof.Some embodiments disclosed herein wherein the subject is administered a daily dose of no more than 2.5 mg of roflumilast or a pharmaceutically acceptable salt thereof, and no more than 600 mg bupropion or a pharmaceutically acceptable salt thereof.BRIEF DESCRIPION OF DRAWINGS
[0037] 31. Figure 1 depicts the results of an experiment showing that the combination therapy (roflumilast and bupropion) reduced food intake more than either monotherapy or vehicle. 32. Figure 2 depicts a genetic analysis of various metabolic traits related to the molecular targets for roflumilast (i.e., phosphodiesterase) and bupropion (i.e., transporters).
[0038] 33. Figure 3 depicts exemplary clinical dosing schedules for roflumilast and bupropion combinations and illustrates adjustments in the timing of the dose, the dosage amounts, and the dosing combinations.
[0039] DETAILED DESCRIPTION OF THE INVENTION
[0040] 34. The present invention is based on the inventor's finding that roflumilast combined with bupropion reduced food intake more than either agent alone (example 1) and that the treatment with the combination of roflumilast and bupropion for several days led to a reduction of body weight in rodents. Disclosed herein is the use of this combination of agents for treating a compulsive eating disorder such as binge-eating disorder and / or treating overweight or obese individuals for weight loss, maintenance of weight loss, prevention of weight gain, and associated comorbidities and related complications.
[0041] 35. Accordingly, the invention features a method of treating the subject suffering from obesity, overweight, or a compulsive eating disorder by administering to the subject a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof. The therapeutic method described herein can be carried out separately from or in combination with other therapies relating to weight loss or treatments for other disorders associated with overweight for example, diabetes. Also featured are compositions comprising a combination of a PDE4 inhibitor and a neurotransmitter reuptake inhibitor.
[0042] 36. COMPOSITIONSAND EXCIPIENTS: The compositions of the invention include a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof. The PDE4 inhibitor can be roflumilast, apremilast, cilomilast, tetomilast, lirimilast, ibudilast, tofimilast, filaminast, piclamilast, crisaborole, rolipram, theophylline, doxofylline, denbufylline, enprofylline,arofylline, cipamfylline, drotaverine, Gsk256066, E6005, MK-0873, (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl] pyridine, mesopram, N-(3,5-dichloro-4-pyridinyl)-2-[l-(4-fluorobenzyl)-5-hydroxy-lH-indol-3-yl]-2- oxoacetamide, CDC-801, CC-1088, CC-11050, ONO-6126, CC-10004 or MN-001. In some embodiments the PDE4 inhibitor is roflumilast (3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy) benzamide). In some embodiments the PDE4 inhibitor can be, optionally, in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, a mixture of active metabolites.
[0043] 37. The neurotransmitter reuptake inhibitor can be bupropion, sibutramine, diethylpropion, mazindol, tesofensine, or lisdexamfetamine. In some embodiments the neurotransmitter reuptake is bupropion ((RS)-2-(tert-Butylamino)-l-(3-chlorophenyl)propan-l-one). We may also refer to bupropion as a norepinephrine and dopamine reuptake inhibitor. In some embodiments the neurotransmitter reuptake inhibitor can be optionally in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, a mixture of active metabolites. In some embodiments, the method comprises administration of roflumilast and bupropion.
[0044] 38. Bupropion alone or roflumilast alone have been reported to increase food consumption in rodents. Compensatory increases in food consumption minimize weight loss due to increased energy expenditure. In the clinic neither bupropion nor roflumilast alone are approved to treat a compulsive eating disorder such as binge-eating disorder, obesity, or associated overweight-related comorbidities or metabolic diseases, such as type 2 diabetes. The combined effects of roflumilast and bupropion on food intake or body weight have not been previously reported. 39. Roflumilast and its active metabolite, roflumilast N-oxide, are phosphodiesterase-4 (PDE-4) inhibitors that act by blocking the PDE-4 mediated breakdown of cyclic adenosine monophosphate (cAMP). Roflumilast is indicated as a treatment to reduce the risk of chronic obstructive pulmonary disease, or COPD, and exacerbations in patients with severe COPD associated with chronic bronchitis. Some of the most common adverse reactions contributing to discontinued use of roflumilast are diarrhea, nausea, headache, back pain, influenza, insomnia, and dizziness. This invention also relates to the use of compositions including roflumilast and its analogues, and other PDE4 inhibitors, including but not limited to apremilast, cilomilast, tetomilast, lirimilast, ibudilast, tofimilast, filaminast, piclamilast, crisaborole, rolipram, theophylline, doxofylline, denbufylline, enprofylline, arofylline, cipamfylline, drotaverine, Gsk256066, E6005, MK-0873, (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl] pyridine, mesopram, N-(3,5-dichloro-4-pyridinyl)-2-[l-(4-fluorobenzyl)-5-hydroxy-lH-indol-3-yl]-2- oxoacetamide, CDC-801, CC-1088, CC-11050, ONO-6126, CC-10004 or MN-001, optionally in the form of their racemates, their enantiomers, their diastereomers, their activemetabolites, and mixtures thereof, and optionally their pharmacologically-compatible acid addition salts and optionally their pharmacologically-active metabolites Bupropion and its active metabolites (hydroxybupropion, threohydrobupropion and erythrohydrobupropion) antagonize the nicotinic acetylcholine receptor and are norepinephrine transporter (SLC6A2) and dopamine transporter (SLC6A3) inhibitors. The renal proximal tubular organic cation transporter (SLC22A2, aka 0CT2) participates in the efflux of bupropion which we propose is related to its mechanism of action. Inhibition of peripheral norepinephrine and dopamine reuptake by bupropion promotes adrenergic and dopamine receptor activity.
[0045] 40. Bupropion is indicated as a treatment for adult depression, seasonal affective disorder, and smoking cessation. Common adverse reactions associated with bupropion treatment include insomnia, rhinitis, dry mouth, dizziness, nervous disturbance, anxiety, nausea, constipation, and arthralgia, agitation, constipation, headache / migraine, nausea / vomiting, excessive sweating, tremor, blurred vision, tachycardia, confusion, rash, hostility, cardiac arrhythmias, and auditory disturbance. Warnings and Precautions for bupropion include seizure, neuropsychiatric adverse events, and suicide risk. This invention also relates to the use of compositions including other neurotransmitter reuptake inhibitors, including but not limited to sibutramine, diethylpropion, mazindol, tesofensine, lisdexamfetamine optionally in the form of their racemates, their enantiomers, their diastereomers, their active metabolites, and mixtures thereof, and optionally their pharmacologically compatible acid addition salts and optionally their pharmacologically active metabolites.
[0046] 41. The pharmaceutical formulations disclosed herein include one or more pharmaceutically acceptable carriers. We use the terms "pharmaceutically acceptable" (or "pharmacologically acceptable") to refer to molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal or a human, as appropriate. The phrase "pharmaceutically acceptable carrier or excipient" refers to a pharmaceutically-acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, solvent, or encapsulating material. Excipients or carriers are generally safe, nontoxic and neither biologically nor otherwise undesirable and include excipients or carriers that are acceptable for veterinary use as well as human pharmaceutical use. See, e.g., P. Beringer, et al., (Eds.), Remington: The Science and Practice of Pharmacy, 21st Ed.; (Lippincott Williams & Wilkins: Philadelphia, Pa., 2005); A. Adejare (Ed.), Remington, The Science and Practice of Pharmacy, 23rd Ed., (Elsevier, 2020); R. C. Rowe et al., Eds., Handbook of Pharmaceutical Excipients, 6th Ed.; (Pharmaceutical Press, 2009); P. J. Shesky et al., Eds., Handbook of Pharmaceutical Excipients, 9th Ed.; (The Pharmaceutical Press, 2020); M. Ash, et al., (Eds.), Handbook of Pharmaceutical Additives, 3rd Ed.; (GowerPublishing Company: 2007); and M. Gibson (Ed.), Pharmaceutical Preformulation and Formulation, 2nd Ed. (CRC Press LLC, 2009).
[0047] 42. The active agents of the present disclosure are prepared as, or comprised in, pharmaceutical compositions. In certain embodiments, such compositions comprise one or more active agent of the present disclosure (e.g.. a PDE4 inhibitor and a neutrotransmitter reuptake inhibitor and one or more therapeutically acceptable excipients (e.g, carrier, solvent, or delivery vehicle). In some embodiments, pharmaceutical compositions comprise a therapeutically effective amount of roflumilast. In some embodiments, pharmaceutical compositions comprise a therapeutically effective amount of bupropion.
[0048] 43. The compositions can be administered by a variety of routes, such as oral or parenteral or topical. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal intramuscular or injection or infusion; or intracranial, e.g., intrathecal or intraventricular, administration. Parenteral administration can be in the form of a single bolus dose, or may be, e.g., by a continuous perfusion pump. Pharmaceutical compositions and formulations for topical administration may include transdermal patches, ointments, lotions, creams, gels, drops, suppositories, sprays, liquids and powders. Conventional pharmaceutical carriers, aqueous, powder or oily bases, thickeners and the like may be useful.
[0049] 44. The pharmaceutical compositions disclosed herein contain, as the active ingredient, the compound of the present disclosure or a pharmaceutically acceptable salt thereof, in combination with one or more pharmaceutically acceptable carriers or excipients. In preparing the compositions of the present disclosure, the active ingredient is typically mixed with an excipient, diluted by an excipient or enclosed within such a carrier in the form of, e.g. , a capsule, sachet, paper, or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, e.g., up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions and sterile packaged powders.
[0050] 45. In preparing a formulation, the active compound can be milled to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it can be milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size can be adjusted by milling to provide a substantially uniform distribution in the formulation, e.g., about 40 mesh. The compounds of the present disclosure may be milled using known milling procedures such as wet milling to obtain a particlesize appropriate for tablet formation and for other formulation types.
[0051] 46. Examples of useful excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup and methyl cellulose. The formulations can additionally include: lubricating agents such as talc, magnesium stearate and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxybenzoates; sweetening agents; and flavoring agents. The compositions of the present disclosure can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the patient
[0052] 47. In some embodiments, the pharmaceutical composition comprises silicified microcrystalline cellulose (SMCC) and at least one compound described herein, or a pharmaceutically acceptable salt thereof. In some embodiments, the silicified microcrystalline cellulose comprises about 98% microcrystalline cellulose and about 2% silicon dioxide w / w.
[0053] 48. In some embodiments, the composition is a sustained release composition comprising at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one pharmaceutically acceptable carrier or excipient. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and at least one component selected from microcrystalline cellulose, lactose monohydrate, hydroxypropyl methylcellulose and polyethylene oxide. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and hydroxypropyl methylcellulose. In some embodiments, the composition comprises at least one compound described herein, or a pharmaceutically acceptable salt thereof, and microcrystalline cellulose, lactose monohydrate and polyethylene oxide. In some embodiments, the composition further comprises magnesium stearate or silicon dioxide. In some embodiments, the microcrystalline cellulose isAvicel PH 102™. In some embodiments, the lactose monohydrate is Fast-flo 316™. In some embodiments, the hydroxypropyl methylcellulose is hydroxypropyl methylcellulose 2208 K4M (e.g., Methocel K4 M Premier™) and / or hydroxypropyl methylcellulose 2208 K100LV (e.g., Methocel KOOLV™). In some embodiments, the polyethylene oxide is polyethylene oxide WSR 1105 (e.g., Polyox WSR 1105™). In some embodiments, a wet granulation process is used to produce the composition. In some embodiments, a dry granulation process is used to produce the composition.
[0054] 49. The compositions can be formulated in a unit dosage form, each dosage containing from about 0.1 mg to about 1 ,000 mg (1 g), more generally about 100 mg to about 500 mg, of the active ingredient. In some embodiments, each dosage contains about 10 mg of the activeingredient. In some embodiments, each dosage contains about 0.25 mg of the active ingredient. In some embodiments, each dosage contains about 75 mg of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient.
[0055] 50. The components used to formulate the pharmaceutical compositions are of high purity and are substantially free of potentially harmful contaminants (e.g., at least National Food grade, generally at least analytical grade, and more typically at least pharmaceutical grade). Particularly for human consumption, the composition is preferably manufactured or formulated under Good Manufacturing Practice standards as defined in the applicable regulations of the U.S. Food and Drug Administration.
[0056] 51. For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present disclosure. When referring to these preformulation compositions as homogeneous, the active ingredient is typically dispersed evenly throughout the composition so that the composition can be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules. This solid preformulation is then subdivided into unit dosage forms of the type described above containing from, e.g., about 0.1 to about 1000 mg of the active ingredient of the present disclosure.
[0057] 52. The tablets or pills of the present disclosure can be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol and cellulose acetate.
[0058] 53. The liquid forms in which the compounds and compositions of the present disclosure can be incorporated for administration orally or by injection include aqueous solutions, suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
[0059] 54. Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. Theliquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions can be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device can be attached to a face mask, tent, or intermittent positive pressure breathing machine.
[0060] Solution, suspension, or powder compositions can be administered orally or nasally from devices which deliver the formulation in an appropriate manner. Topical formulations can contain one or more conventional carriers. In some embodiments, ointments can contain water and one or more hydrophobic carriers selected from, e.g., liquid paraffin, polyoxyethylene alkyl ether, propylene glycol, white Vaseline, and the like. Carrier compositions of creams can be based on water in combination with glycerol and one or more other components, e.g., glycerinemonostearate, PEG-glycerinemonostearate and cetylstearyl alcohol. Gels can be formulated using isopropyl alcohol and water, suitably in combination with other components such as, e.g., glycerol, hydroxyethyl cellulose, and the like. In some embodiments, topical formulations contain at least about 0.1 , at least about 0.25, at least about 0.5, at least about 1, at least about 2 or at least about 5 wt% of the compound of the present disclosure. The topical formulations can be suitably packaged in tubes of, e.g., 100 g which are optionally associated with instructions for the treatment of the select indication.
[0061] 55. The therapeutic dosage of a compound of the present disclosure can vary according to, e.g., the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the present disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. For example, the compounds of the present disclosure can be provided in an aqueous physiological buffer solution containing about 0.1 to about 10% w / v of the compound for parenteral administration. Some typical dose ranges are from about 1 ,ug / kg to about 1 g / kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg / kg to about 100 mg / kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of progression of the disease or disorder, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from doseresponse curves derived from in vitro or animal model test systems. The combined active ingredients of both the PDE4 inhibitor (roflumilast) and neurotransmitter reuptake inhibitor (e.g., bupropion) can be formulated within a single tablet or capsule which includes excipients. The excipients included in the formulation are not limited tobut include common excipients such as magnesium stearate, lactose monohydrate, cornstarch, polyvinylpyrrolidone (povidone), glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl alcohol, polyethylene glycol, silicon dioxide, triethyl citrate, magnesium silicate, titanium dioxide, carnauba wax, cysteine hydrochloride, polysorbate 80, and mixtures thereof, and optionally pharmacologically related excipients. This invention also relates to formulations using Natrosol hydroxyethyl cellulose (used in examples 1 and 2) or related excipients, such as ethylcellulose, methylcellulose, hydroxypropyl cellulose, hypromelloses, or microcrystalline cellulose
[0062] 56. METHODS OF TREATMENT The compositions disclosed herein are generally and variously useful for treatment of a subject suffering from obesity, overweight, a compulsive eating disorder or a subject who is at risk for a compulsive eating disorder. We may refer to a subject, patient, or individual interchangeably. A subject is effectively treated whenever a clinically beneficial result ensues. This may mean, for example, weight loss or weight loss such that the patient no longer suffers from obesity, or a reduction in compulsive eating. In some embodiments, the clinical beneficial result can be maintenance of the patient's weight once the weight loss has taken place. These methods can further include the steps of a) identifying a subject (e.g., a patient and, more specifically, a human patient or animal) who suffers from obesity, overweight, or a compulsive eating disorder; and b) providing to the subject a composition comprising a PDE4 inhibitor and a neurotransmitter reuptake inhibitor.. A subject can be identified using standard clinical methods, for example, physical or psychological examination. An amount of such a composition provided to the subject that results in weight loss or weight loss such that the patient no longer suffers from obesity, or a reduction in compulsive eating is considered a therapeutically effective amount. The present methods may also include a monitoring step to help optimize dosing and scheduling as well as predict outcome. Monitoring can also be used to detect the onset of drug resistance and to rapidly distinguish responsive patients from nonresponsive patients.
[0063] 57. The term "effective" as used herein refers to any amount that induces a desired response while not inducing significant toxicity in the patient. Such an amount can be determined by assessing a patient's response after administration of a known amount of a particular composition. In addition, the level of toxicity, if any, can be determined by assessing a patient's clinical symptoms before and after administering a known amount of a particular composition. It is noted that the effective amount of a particular composition administered to a patient can be adjusted according to a desired outcome as well as the patient's response and level of toxicity. Significant toxicity can vary for each particular patient and depends on multiple factors including, without limitation, the patient's disease state, age, and tolerance to side effects.58. The therapeutic dosage of a compound of the present disclosure can according to, for example, the particular use for which the treatment is made, the manner of administration of the compound, the health and condition of the patient, and the judgment of the prescribing physician. The proportion or concentration of a compound of the present disclosure in a pharmaceutical composition can vary depending upon a number of factors including dosage, chemical characteristics (e.g., hydrophobicity), and the route of administration. Some typical dose ranges are from about 1 pg / kg to about 1 g / kg of body weight per day. In some embodiments, the dose range is from about 0.01 mg / kg to about 100 mg / kg of body weight per day. The dosage is likely to depend on such variables as the type and extent of overweight, the overall health status of the particular patient, the relative biological efficacy of the compound selected, formulation of the excipient, and its route of administration. Effective doses can be extrapolated from dose response curves derived from in vitro or animal model test systems. Concurrent administration of two or more therapeutic agents does not require that the agents be administered at the same time or by the same route, as long as there is an overlap in the time period during which the agents are exerting their therapeutic effect. Simultaneous or sequential administration is contemplated, as is administration on different days or weeks. So, for example, the PDE4 inhibitor, e.g., Roflumilast, and the neurotransmitter reuptake inhibitor, e.g., bupropion may be administered on the same day at the same time or on the same day at different times, or on different days at the same time, or on different days at different times.
[0064] 59. The present disclosure relates to administering a daily dose to a subject of no less than 0.1 mg of roflumilast or a pharmaceutically acceptable salt thereof, and no less than 30 mg bupropion, or a pharmaceutically acceptable salt thereof. Thus, for example the daily dose of roflumilast can be about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, or about 2.5 mg. Thus, for example the daily dose of bupropion can be about 30 mg, about 5 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85, mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 600 mg.
[0065] 60. The duration of treatment with any composition provided herein can be any length of time from as a few weeks to as long as the life span of the subject (e.g., many years). For example, a compound can be administered daily (for, for example, 4 weeks, 5 weeks, 6 weeks, 8 weeks, 12 weeks to many months or years. In some embodiments, the PDE4 inhibitor, e.g., roflumilast, and the neurotransmitter reuptake inhibitor, e.g., bupropion, are each administered daily at a fixed dosefor 28 days. The fixed daily dose of Roflumilast can be for example about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, or about 2.5 mg. Useful initial doses of Roflumilast include 0.25 mg or 0.5 mg. The fixed daily dose of bupropion can be, for example about 30 mg, about 5 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85, mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 600 mg. Useful initial doses of bupropion include 75 mg or 100 mg. Regardless of the dosage, in some embodiments doses of the compounds can be increased or decreased after a few days or weeks, for example, four weeks, five weeks, six weeks, 12 weeks. Thus, in some embodiments, following the initial daily dosing of 0.25 mg of Roflumilast and 75 mg of bupropion, the daily doses of the compounds can be increased, for example the Roflumilast is increased to a daily dose of 0.5 mg and that bupropion is increased to a daily dose of 100 mg. In some embodiments, following the initial daily dosing of 0.5 mg of Roflumilast and 100 mg of bupropion, the daily doses of the compounds can be decreased, for example the Roflumilast is decreased to a daily dose of 0.25 mg and that bupropion is decreased to a daily dose of 75 mg.
[0066] 61. In some embodiments, the patient can receive either the PDE4 inhibitor, for example roflumilast, or the neurotransmitter reuptake inhibitor, for example bupropion, for a period prior to receiving the combination of the two agents. For example, a daily dose of Roflumilast can be administered for one day, two days, three days, one week, two weeks, three weeks, four weeks, five weeks, or six weeks prior to the administration of the combination of Roflumilast and bupropion. For example, a daily dose of bupropion can be administered for one day, two days, three days, one week, two weeks, three weeks, four weeks, five weeks, or six weeks prior to the administration of the combination of roflumilast and bupropion.
[0067] 62. In some embodiments, the compositions can be administered either prior to or following treatment with a weight-loss promoting agent. The weight-loss promoting agent can be the an agent targeting the GLP1 receptor, e.g., semaglutide, liraglutide, danuglipron, or a dual GIP / GLP-1 receptor co-agonist, e.g., tirzepatide, or a dual amylin / GLP-1 receptor co-agonist, e.g., amycretin. In some embodiments, the agent promoting weight loss is an agent inhibiting glucose absorption, for example an SGLT sodium glucose transporter inhibitor, e.g., empagliflozin, or an alphaglucosidase inhibitor, e.g., acarbose. In some embodiments, the agent promoting weight loss is an agent inhibiting lipid absorption, e.g., the pancreatic lipase inhibitor, orlistat, or the microsomal transfer protein inhibitor, lomitapide. In some embodiments, particularly for a subject suffering from compulsive eating disorder or is subject to is at risk for compulsive eating disorder, thecompositions can be administered either prior to or following treatment with an agent directed to the nervous system. In some embodiments, the agent can be a central nervous system agent, e.g. lisdexamfetamine dimesylate, topiramate, a selective serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant.
[0068] 63. The weight-loss promoting agent or the central nervous system targeting agent can be administered for at least one day, at least two days, at least three days, at least one week, at least two weeks, at least three weeks, at least four weeks, at least five weeks, at least six weeks, at least 12 weeks, at least four months, at least five months, at least six months, at least 12 months, at least 18 months, or at least two years or more prior to the administration of the combination of Roflumilast and bupropion
[0069] 64. DISORDERS / DISEASES: The present disclosure relates to compositions, uses, kits, systems, and methods for treating a compulsive eating disorder such as binge-eating disorder by using a combination of a norepinephrine and dopamine reuptake inhibitor, such as bupropion, and a phosphodiesterase 4 (PDE4) inhibitor, such as roflumilast, or pharmaceutically acceptable salts or prodrugs thereof. Binge-eating disorder is often accompanied by eating rapidly over a short period of time, eating when the subject is not hungry and is uncomfortably full, or uncontrolled eating that can affect the subject's feelings or behavior. While roflumilast or bupropion alone have been reported to have little effect or increase food intake in preclinical studies, we made the unexpected observation that the combination of both agents significantly reduced food intake in rodents more than either monotherapy as shown in example 1, indicating the combination can be useful in the treatment of disorders (e.g., a compulsive eating disorder such as binge-eating disorder, obesity) related to excess food intaThe present disclosure relates to compositions, uses, kits, systems, and methods for treating weight-related comorbidities by using a combination of a norepinephrine and dopamine reuptake inhibitor, such as bupropion, and a phosphodiesterase 4 (PDE4) inhibitor, such as roflumilast, or pharmaceutically acceptable salts or prodrugs thereof. In some embodiments the subject is obese with a body mass index (BMI) of 30kg / m2or greater or the subject is overweight with a BMI of between 25 kg / m2and 30 kg / m2with the presence or absence of at least one weight-related comorbidity, such as hypertension, type 2 diabetes mellitus, dyslipidemia, non-alcoholic steatohepatitis, or macro- or micro-vascular complications. The treated subject may fit the current or future clinical descriptions in accordance with the FDA Guidance for Industry Developing Products for Weight Management. Approximately 60-70% of overweight or obese subjects have weight-related comorbidities, such as mixed dyslipidemia or lipid abnormalities, including elevated serum triglyceride, total cholesterol or LDL-cholesterol levels or reduced HDL-cholesterol levels. By comparison, roughly 30 percent of overweightpeople have type 2 diabetes (high fasting glucose) and 40% of the obese population has hypertension. This cluster of abnormalities (elevated body fat, blood lipid levels, blood pressure and glucose), referred to as metabolic syndrome, is associated with the development of cardiovascular disease. Obesity, excess body fat, and dyslipidemia are also related to elevated levels of biomarkers of liver or kidney function, such as elevated transaminases (ALT, AST) or elevated uric acid and creatinine, respectively. Nonalcoholic steatohepatitis, or NASH, is the most severe form of nonalcoholic fatty liver disease (NAFLD), a condition in which the liver builds up excessive fat deposits. Gout, which is associated with elevated uric acid levels, and chronic kidney disease, which is associated with reduced estimated glomerular filtration rate (EGFRcreat) are more common in dyslipidemic, overweight and obese subjects. In some embodiments, a combination of PDE4 inhibitors, such as roflumilast, and neuro-transporter inhibitors, such as bupropion, can be used to treat metabolic syndrome as well as overweight and obese subjects with weight-associated comorbidities, such as dyslipidemia, diabetes, liver and / or kidney diseases.
[0070] 65. In some embodiments, the methods and compositions disclosed herein can be used for the treatment of a companion animal suffering from overweight or obesity. The companion animal can be, for example, a dog or a cat. The dog can be a mixed breed or a purebred dog. The dog can be, including for example, without limitation, a pet, a service dog, a police dog, a military working dog, a detection dog, a search and rescue dog, a herding dog, or a guard dog. The administration of the compositions can be in accordance with veterinarian best practice, including, but not limited to professional, regulatory, or government treatment guidelines, wherein the treatment is useful for treatment of excess body weight and / or excess fat in the companion animal.
[0071] 66. DOSAGES: We identified bupropion and roflumilast as a novel combination of agents to be included in treatment strategies to effectively treat subjects with eating disorders or treat subjects that are overweight or obese. We examined 1) the ability of the combination to reduce food intake more than either agent alone in rodents, 2) the ability of the combination to reduce weight gain in rodents, and 3) the potential to improve the relative benefit-to-risk ratio by adjusting the dose. Accordingly, the present invention is directed to using a dose adjusting strategy for administering a neurotransmitter reuptake inhibitor, such as bupropion, in combination with PDE-4 inhibitor, such as roflumilast, such that the combination reduce food intake to a greater degree than when either agent is used alone, thereby improving therapeutic outcomes related to food intake and body weight.
[0072] 67. The present disclosure relates to administering a daily dose to a subject of no less than 0.1 mg of roflumilast or a pharmaceutically acceptable salt thereof, and no less than 30 mgbupropion, or a pharmaceutically acceptable salt thereof. Thus, for example the daily dose of roflumilast can be about 0.1 mg, about 0.15 mg, about 0.2 mg, about 0.25 mg, about 0.3 mg, about 0.4 mg, about 0.5 mg, about 0.6 mg, about 0.7 mg, about 0.8 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, or about 2.5 mg. Thus, for example the daily dose of bupropion can be about 30 mg, about 5 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85, mg, about 90 mg, about 95 mg, about 100 mg, about 125 mg, about 150 mg, about 175 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg or about 600 mg.
[0073] 68. In some embodiments, the subject is a companion animal weighing over 2 kg, wherein the subject is administered no less than one daily dose of 0.013 mg roflumilast or a pharmaceutically acceptable salt thereof and no less than one daily dose of 4 mg bupropion or a pharmaceutically acceptable salt. In some embodiments, the subject is a companion animal weighing under 70 kg, wherein the subject is administered no more than two daily doses of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and no more than two daily doses of 75 mg bupropion or a pharmaceutically acceptable salt.
[0074] 69. The present disclosure relates to starting off with a low dose, and after building tolerability to potential side effects, then increasing the daily dose to improve efficacy. The present disclosure relates to administering a daily dose to a subject of no more than 2.5 mg of roflumilast or a pharmaceutically acceptable salt thereof, and no more than 600 mg bupropion or a pharmaceutically acceptable salt thereof. The present disclosure relates to reducing the maximal dose after achieving desired efficacy and then continue dosing to maintain efficacy and / or improve tolerability. Dosing adjustments are further exemplified in example 3.
[0075] 70. ARTICLES OF MANUFACTURE. The compositions described herein can be packaged in suitable containers labeled, for example, for use as a therapy to treat a subject suffering from overweight, obesity, compulsive eating disorder, or who is at risk for compulsive eating disorder.
[0076] 71. The containers can include a composition comprising a PDE4 inhibitor, for example roflumilast, and a neurotransmitter reuptake inhibitor, for example, bupropion. The components can be in a tablet or capsule form comprising a suitable excipient as appropriate for intended use. Accordingly, packaged products (e.g., sterile containers containing one or more of the compositions described herein and packaged for storage, shipment, or sale at concentrated or ready-to-use concentrations) and kits, including at least one comprising a PDE inhibitor, for example Roflumilast, and a neurotransmitter reuptake inhibitor, for example bupropion, and instructions for use, are also within the scope of the invention. A product can include a container (e.g., a vial, jar, bottle, bag, or the like) containing one or more compositions of the invention. In addition, an article of manufacture further may include, forexample, packaging materials, instructions for use, syringes, delivery devices, buffers or other control reagents for treating or monitoring the condition for which prophylaxis or treatment is required.
[0077] 72. The product may also include a legend (e.g., a printed label or insert or other medium describing the product's use). The legend can be associated with the container (e.g., affixed to the container) and can describe the manner in which the compositions therein should be administered (e.g., the frequency and route of administration), indications therefor, and other uses. The compositions can be ready for administration (e.g., present in dose-appropriate units), and may include one or more additional pharmaceutically acceptable adjuvants, carriers or other diluents and / or an additional therapeutic agent.
[0078] 73. EXAMPLES: METHODS: The effects on food intake were measured over an 8-hour period in male Swiss- Webster mice treated with vehicle (0.5% Natrosol hydroxyethyl cellulose, 5mL / kg), 35 mg / kg bupropion, 1 mg / kg roflumilast or 35 mg / kg bupropion combined with 1 mg / kg roflumilast. Mice (N=32) at 6-7 weeks of age were fed a high fat diet (60% energy from fat) for two weeks, dosed with one of the four indicated treatments (vehicle, roflumilast, bupropion, or combined roflumilast and bupropion), and food was weighed before and 8 hours after dosing. The average weight of the mice at the time of dosing was 38.6 grams. Outliers were identified and excluded following the 95-rule of outliers and the averages, standard deviations, and t-tests (one-tailed, two-sample equal variance) were calculated for food intake in each group using Microsoft Excel.
[0079] 74. The effects of combination therapy on body weight were examined in diet-induced obese mice. By way of brief description, male Swiss Webster mice (6-7 weeks of age) were fed a high fat diet (60% energy from fat) for two weeks and subsequently dosed twice daily with either vehicle or the combination of roflumilast and bupropion in vehicle. The mice were initially given vehicle (0.5% Natrosol hydroxyethyl cellulose), or 35 mg / kg bupropion combined with 1 mg / kg roflumilast, twice daily for 10 doses. Side effects (e.g., seizure) attributed to bupropion were observed in two mice within the first week of the study. Thus, to improve tolerability, the mice were allowed two days of recovery before giving a lower dose of 8.75 mg / kg bupropion combined with 0.25 mg / kg roflumilast, twice daily for the last 8 doses.
[0080] 75. EXAMPLE 1, PRECLINICAL PHARMACOLOGY: To explore whether the combination of bupropion and roflumilast alters food intake more than monotherapy or vehicle, food intake was measured for 8 hours following treatment of male Swiss-Webster mice on a high fat diet with vehicle, bupropion, roflumilast or a combination of roflumilast and bupropion (n=8 per arm). As depicted in FIG 1, the combination therapy but not the monotherapies reduced food intake. We showed that roflumilast monotherapy significantly (P=0.039) increased food intake relative to vehicle whereas bupropion monotherapy had no significant (P=0.137) effect on food intake inthese mice. In contrast to monotherapy, we made the unexpected finding that the combination of roflumilast and bupropion significantly (P<0.01) reduced food intake. Both roflumilast and bupropion monotherapies have been reported to increase food intake in rodents, however it was unknown if the agents could be used together to reduce food intake or weight gain. Thus, food intake was significantly reduced using the combined treatment of roflumilast and bupropion relative to vehicle or monotherapy treated mice. These data suggested that the combination of bupropion and roflumilast may be useful in treating disorders related to excess food intake, such as a compulsive eating disorder such as binge-eating disorder, being overweight or obese, and weight-related comorbidities.
[0081] 76. We explored whether the combination treatment of bupropion and roflumilast would reduce weight gain in diet-induced obese mice after 18 doses of each drug. At the end of the dosing, we found that the combination treatment of bupropion and roflumilast led to a meaningful reduction of body weight gain in the diet-induced obese mice relative to vehicle treated mice (P=0.05). The mice treated with vehicle (N=5) gained 2.62 ±1.81 grams whereas the mice treated with the combination (n=6) of both roflumilast and bupropion gained 0.86±1.43 grams. The effect of combining bupropion and roflumilast to reduce body weight gain was previously unknown. Thus, weight gain was reduced by 67% using the combined treatment of roflumilast and bupropion relative to vehicle-only treated mice. These data suggested that the combination of bupropion and roflumilast may be useful in treating obesity and disorders related to excess body weight. 77. Bupropion alone or roflumilast alone have been reported to increase food consumption in rodents. Compensatory increases in food consumption minimize weight loss due to increased energy expenditure. In the clinic, neither bupropion nor roflumilast alone are approved to treat a compulsive eating disorder such as binge-eating disorder, obesity, or associated overweight-related comorbidities or metabolic diseases. The combined effects of roflumilast and bupropion on food intake have not been previously reported.
[0082] 78. EXAMPLE 2, GENETIC ANALYSIS: Roflumilast has at least 4 potential molecular targets (PDE4A, PDE4B, PDE4C, PDE4D) and bupropion has at least 4 potential molecular targets (SLC6A2, SLC6A3, SLC22A2, CHRNA3). It is unknown which of these targets contribute to the effects of roflumilast and bupropion on food intake and body weight. Given there are eight potential targets contributing to the effect of these combined drugs on food intake and / or body weight, we performed a detailed genetic analysis using the type 2 diabetes knowledge portal (https: / / t2d.hugeamp.org / ) to identify which two complimentary targets were candidates contributing to their combined beneficial effect on obesity and its related traits.
[0083] 79. FIG. 2 illustrates the p-values from the genetic analysis of various metabolic traits related tothe proposed molecular targets for roflumilast and bupropion. To account for multiple testing in genome-wide association studies (GWAS), a fixed P-value threshold of 5e-8 (in bold) was used to identify association between a common genetic variant and a trait of interest while the threshold for a suggestive significant association is commonly le-5 (in italics). Select markers and risk factors for obesity, dyslipidemia, cardiovascular, kidney and liver disease were provided which show significant associations with both PDE4C and SLC22A2. FIG. 2 shows of the four PDE4 isoforms, PDE4C had the strongest association with obesity related traits. Analysis of human PDE4C reveals significant common variant gene-level associations for waist-hip ratio (1.26e-32), BMI (7.84e-14) and body weight (4.13e-13) and the human genetic evidence quantifies strong evidence for involvement of PDE4C in visceral adipose tissue and abdominal subcutaneous adipose tissue volume (PDE4C Gene page. 2023 April 29; https: / / t2d.hugeamp.org / gene.html?gene=PDE4C (RRID:SCR 003743)). Of the three transporters (SLC6A2, SLC6A3, SLC22A2) and the nicotinic acetylcholine receptor (CHRNA3) targets for bupropion, the most common genetic variants for weight, triglyceride levels, and BMI were associated the SLC22A2 gene. Analysis of human SLC22A2 variant associations revealed associations with waist-hip ratio (p= 4.08e-8), triglyceride levels (p=3.25e-10) and BMI (p= 1.71e-6) (SLC22A2 Gene page. 2023 April 29; https: / / t2d.hugeamp.org / gene.html?gene=SLC22A2 80. (RRID:SCR 003743)). Given that 1) PDE4C common genetic variants are associated with waist to hip ratio, BMI, and related traits, 2) SLC22A2 common genetic variants are associated with weight and various obesity-related comorbidities (dyslipidemia markers: triglyceride, APO-B), and 3) combining roflumilast and bupropion reduced both food intake (FIG 1) and weight in rodents, we suggest that selectively inhibiting PDE4C and SLC22A2 will promote satiety and be useful in treating obesity and its associated complications and diseases.
[0084] 81. EXAMPLE 3, CLINICAL UTILITY: Obesity is often estimated using body mass index (BMI) calculations. BMI is calculated as weight (kg) / [height (m)].2. According to the guidelines of the U.S. Center for Disease Control and Prevention (CDC) and the World Health Organization (WHO), for adults over 20 years old, a BMI between 25.0-29.9 is considered overweight, and 30.0 and greater is considered obese and a health risk factor (World Health Organization. Physical status: The use and interpretation of anthropometry. Geneva, Switzerland: World Health Organization 1995. WHO Technical Report Series). The waist-to-hip ratio (WHR) calculation is another way to determine if excess weight is a health risk. People who have a WHR greater than 1 carry more visceral fat in their midsection and are at an increased risk of heart disease, type 2 diabetes, and premature death relative to lean individuals.
[0085] 82. Industry guidance for developing products for weight management is available fromgovernment organizations. The U.S. Department of Health and Human Services (DHHS) Food and Drug Administration (FDA) Center for Drug Evaluation and Research (CDER) regulatory guidance supports the pharmaceutical treatment of overweight or obese individuals. Current FDA guidance indicates that pharmaceutical treatment should be used as an adjunct to diet and exercise for chronic weight management in adults with an initial BMI of 30 kg / m2or greater (obese) or 27 kg / m2or greater (overweight with a comorbidity) in the presence of at least one weight-related comorbidity (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia).
[0086] 83. Examples of clinical dosing schedules are provided in FIG 3. The timing of dose adjustments as well as the dosage amounts and combinations thereof may be varied to achieve a dosing schedule possessing different efficacy and tolerability characteristics. Wherein examples are provided for adjusting the doses, these compositions and dosing schedules are intended to be exemplary and the specific procedures, constituents, amounts thereof and the like may be varied to obtain desired clinical outcomes. Treated subjects may include individuals with binge eating disorder, overweight (BMI 25 to < 30) subjects with or without a comorbid
[0087] complication, uncomplicated class 1 obese (BMI 30-34.9) adults or obese class 2 (BMI >34.9) adults with lifestyle / behavioral modifications. Various initial and follow-up dosing schedules are followed to improve the benefit / risk ratio and regulate body weight, food intake, safety and / or tolerability issues. Monotherapy, prior to combination (Schedules 1, 2, 5): Treat with low dose of at least 75 mg Bupropion for 3 days (schedule 1), which is expected to improve tolerability; reduce seizure risk), OR treat with a low dose of at least 0.25 mg roflumilast for 1 month (Schedule 2) which is expected to improve Gl tolerability, OR treat with an approved agent for weight loss (e.g., GLP1 analogues) (Schedule 5). After building tolerance to the initial monotherapy, initiate treatment with a combination of roflumilast or bupropion, respectively, to improve weight loss. Low dose prior to high dose combinations (Schedule 3): Simultaneously combine low doses of at least 0.25 mg roflumilast AND of at least 75 mg Bupropion and continue treatment for a minimum of 4 weeks. Starting with low doses of combined agents for four weeks prior to raising the dose is expected to reduce tolerability issues. After 4 weeks of low dose treatment with combined agents, increase total daily dose of either one or both agents for 12 weeks to promote weight loss, without exceeding 0.5 mg roflumilast or 450 mg of bupropion in the combination product. Triple Therapy (Schedules 4-5): If additional weight loss is desired then roflumilast plus bupropion can be added before or after treatment with additional weight loss agents, such as an SGLT inhibitor, MTP inhibitor, or Lipase inhibitor or GLP1 receptor agonist. Reduced dose (schedule 6): Reduce total dose or number of treatments to decrease treatment-induced weight loss or improve tolerability of the treatments. The lower dose can be adjusted and maintained for optimal efficacy and tolerability for a treated subject.84. EXAMPLE 4. CLINICAL TESTING. In an ongoing clinical trial, patients suffering from obesity were treated with roflumilast and bupropion. Initial results demonstrated safety and tolerability as well as substantial weight loss.
Claims
CLAIMS1. A method of treating a subject suffering from overweight or obesity, comprising administeringto the subject a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof, wherein the treatment provides weight management.
2. The method of claim 1 , wherein the PDE4 inhibitor is selected from the group consisting of roflumilast, apremilast, cilomilast, tetomilast, lirimilast, ibudilast, tofimilast, filaminast, piclamilast, crisaborole, rolipram, theophylline, doxofylline, denbufylline, enprofylline, arofylline, cipamfylline, drotaverine, Gsk256066, E6005, MK-0873, (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine, mesopram, N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1 H-indol-3-yl]-2- oxoacetamide, CDC-801 , CC-1088, CC-11050, ONO-6126, CC-10004 and MN-001.
3. The method of claim 2, wherein the PDE4 inhibitor is optionally in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, ora mixture of active metabolites.
4. The method of claim 1 , wherein the neurotransmitter reuptake inhibitor is selected from the group consisting of bupropion, sibutramine, diethylpropion, mazindol, tesofensine, and lisdexamfetamine.
5. The method of claim 4, wherein the neurotransmitter reuptake inhibitor is optionally in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, a mixture of active metabolites.
6. The method of claim 1 , wherein the subject is human.
7. The method of claim 6, further comprising the step of identifying the subject.
8. The method of claim 1 , wherein the PDE4 inhibitor comprises roflumilast.
9. The method of claim 8, wherein the roflumilast is administered at a dose of between about 0.1 mg and between about 1.5 mg.
10. The method of claim 8, wherein the roflumilast is administered daily.
11. The method of claim 1 , wherein the neurotransmitter reuptake inhibitor comprises bupropion.
12. The method of claim 11 , wherein the bupropion is administered at a dose of between about 30 mg and between about 600 mg.
13. The method of claim 11 , wherein the bupropion is administered daily.
14. The method of any of claims 8-13 comprising administering roflumilast, ora pharmaceutically acceptable salt thereof and bupropion, or a pharmaceutically acceptable salt thereof.
15. The method claim 14, wherein the roflumilast is administered in a single daily dose of 0.25 mg and the bupropion is administered in a single daily dose of 75 mg.
16. The method of claim 14, wherein the roflumilast is administered in a single daily dose of 0.5 mg and the bupropion is administered in a single daily dose of 100 mg.
17. The method of claim 14, wherein the roflumilast and the bupropion are administered daily for at least two weeks, at least three weeks, at least four weeks, at least eight weeks, or at least 12 weeks.
18. The method of claim 14, further comprising administering a daily dose of bupropion for at least three days before administration of the combination of roflumilast and bupropion.
19. The method claim 14, further comprising administering a daily dose of roflumilast for at least 4 weeks before administration of the combination of roflumilast and bupropion.
20. The method of claim 14, wherein the roflumilast and the bupropion are administered daily for a period of at least four weeks; and subsequently increasing the total daily dose of roflumilast not to exceed 0.5 mg and the total daily dose of bupropion not to exceed 450 mg of bupropion, for at least 12 weeks.
21. The method of claim 20, wherein the daily dose of roflumilast is subsequently increased to 0.5 mg and the daily dose of bupropion is subsequently increased to 100 mg.
22. The method of claim 14, wherein the roflumilast and the bupropion are administered daily for a period of at least four weeks; and subsequently decreasing the total daily dose of roflumilast not to exceed 0.5 mg and the total daily dose of bupropion not to exceed 450 mg of bupropion, for at least 12 weeks.
23. The method of claim 22, wherein the daily dose of roflumilast is subsequently decreased to 0.25 mg and the daily dose of bupropion is subsequently decreased to 75 mg.
24. The method of claim 14, wherein the bupropion comprises a sustained release formulation.
25. The method of claim 14, wherein the roflumilast and bupropion are formulated separately or together as a capsule or tablet for oral administration.
26. The method of claim 25, wherein the capsule or tablet further comprises one or more excipients selected from the group consisting of magnesium stearate, lactose monohydrate, cornstarch, polyvinylpyrrolidone (povidone), glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl alcohol, polyethylene glycol, silicon dioxide, triethyl citrate, magnesium silicate, titanium dioxide, carnauba wax, cysteine hydrochloride, polysorbate 80, and mixtures thereof.
27. The method of claim 25, wherein the capsule or tablet further comprises hydroxyethyl cellulose, ethylcellulose, hydroxypropyl cellulose, hypromelloses, or microcrystalline cellulose.
28. The method of claim 1 , further comprising subsequently administering to the subject an agent promoting weight loss.
29. The method of claim 28, wherein the agent promoting weight loss is an agent targeting the GLP1 receptor, e.g., semaglutide, liraglutide, danuglipron, or a dual GIP / GLP-1 receptor co-agonist, e.g., tirzepatide, or a dual amylin / GLP-1 receptor coagonist, e.g., amycretin.
30. The method of claim 28, wherein the agent promoting weight loss is an agent inhibiting glucose absorption.
31. The method of claim 28, wherein agent inhibiting glucose absorption is an SGLT sodium glucose transporter inhibitor, e.g., empagliflozin, or an alpha-glucosidase inhibitor, e.g., acarbose.
32. The method of claim 28, wherein the agent promoting weight loss is an agent inhibiting lipid absorption, e.g., the pancreatic lipase inhibitor, orlistat, or the microsomal transfer protein inhibitor, lomitapide.
33. The method of claim 1 , wherein the therapeutic agent of any of claims 28-32 is administered for at least 12 weeks prior to administration of roflumilast and bupropion.
34. A method of treating a subject suffering from a compulsive eating disorder or who is at risk for a compulsive eating disorder, comprising administering to the subject a phosphodiesterase IV (PDE4) inhibitor, or a pharmaceutically acceptable salt thereof, and a neurotransmitter reuptake inhibitor or a pharmaceutically acceptable salt thereof, wherein the treatment reduces food intake.
35. The method of claim 34, wherein the compulsive eating disorder is binge-eating disorder.
36. The method of claim 34, wherein the PDE4 inhibitor is selected from the group consisting of roflumilast, apremilast, cilomilast, tetomilast, lirimilast, ibudilast,tofimilast, filaminast, piclamilast, crisaborole, rolipram, theophylline, doxofylline, denbufylline, enprofylline, arofylline, cipamfylline, drotaverine, Gsk256066, E6005, MK-0873, (R)-(+)-4-[2-(3-cyclopentyloxy-4-methoxyphenyl)-2-phenylethyl]pyridine, mesopram, N-(3,5-dichloro-4-pyridinyl)-2-[1-(4-fluorobenzyl)-5-hydroxy-1 H-indol-3-yl]-2- oxoacetamide, CDC-801 , CC-1088, CC-11050, ONO-6126, CC-10004 and MN-001.
37. The method of claim 36, wherein the PDE4 inhibitor is optionally in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, ora mixture of active metabolites.
38. The method of claim 34, wherein the neurotransmitter reuptake inhibitor is selected from the group consisting of bupropion, sibutramine, diethylpropion, mazindol, tesofensine, and lisdexamfetamine.
39. The method of claim 38, wherein the neurotransmitter reuptake inhibitor is optionally in the form of a racemate, an enantiomer, a diastereomer, an active metabolite, a mixture of active metabolites.
40. The method of claim 34, wherein the subject is human.
41. The method of claim 40, further comprising the step of identifying the subject.
42. The method of claim 34, wherein the PDE4 inhibitor comprises roflumilast.
43. The method of claim 42, wherein the roflumilast is administered at a dose of between about 0.1 mg and between about 1.5 mg.
44. The method of claim 42, wherein the roflumilast is administered daily.
45. The method of claim 34, wherein the neurotransmitter reuptake inhibitor comprises bupropion.
46. The method of claim 45, wherein the bupropion is administered at a dose of between about 30 mg and between about 600 mg.
47. The method of claim 45, wherein the bupropion is administered daily.
48. The method of any of claims 42-47 comprising administering roflumilast, ora pharmaceutically acceptable salt thereof and bupropion, or a pharmaceutically acceptable salt thereof.
49. The method claim 48, wherein the roflumilast is administered in a single daily dose of 0.25 mg and the bupropion is administered in a single daily dose of 75 mg.
50. The method of claim 48, wherein the roflumilast is administered in a single daily dose of 0.5 mg and the bupropion is administered in a single daily dose of 100 mg.
51. The method of claim 48, wherein the roflumilast and the bupropion are administered daily for at least two weeks, at least three weeks, at least four weeks, at least eight weeks, or at least 12 weeks.
52. The method of claim 48, further comprising administering a daily dose of bupropion for at least three days before administration of the combination of roflumilast and bupropion.
53. The method claim 48, further comprising administering a daily dose of roflumilast for at least 4 weeks before administration of the combination of roflumilast and bupropion.
54. The method of claim 48, wherein the roflumilast and the bupropion are administered daily for a period of at least four weeks; and subsequently increasing the total daily dose of roflumilast not to exceed 0.5 mg and the total daily dose of bupropion not to exceed 450 mg of bupropion, for at least 12 weeks.
55. The method of claim 54, wherein the daily dose of roflumilast is subsequently increased to 0.5 mg and the daily dose of bupropion is subsequently increased to 100 mg.
56. The method of claim 48, wherein the roflumilast and the bupropion are administered daily for a period of at least four weeks; and subsequently decreasing the total daily dose of roflumilast not to exceed 0.5 mg and the total daily dose of bupropion not to exceed 450 mg of bupropion, for at least 12 weeks.
57. The method of claim 56, wherein the daily dose of roflumilast is subsequently decreased to 0.25 mg and the daily dose of bupropion is subsequently decreased to 75 mg.
58. The method of claim 48, wherein the bupropion comprises a sustained release formulation.
59. The method of claim 48, wherein the roflumilast and bupropion are formulated separately of together as a capsule or tablet for oral administration.
60. The method of claim 59, wherein the capsule or tablet further comprises one or more excipients selected from the group consisting of magnesium stearate, lactose monohydrate, cornstarch, polyvinylpyrrolidone (povidone), glyceryl behenate, methacrylic acid copolymer dispersion, polyvinyl alcohol, polyethylene glycol, silicon dioxide, triethyl citrate, magnesium silicate, titanium dioxide, carnauba wax, cysteine hydrochloride, polysorbate 80, and mixtures thereof.
61. The method of claim 59, wherein the capsule or tablet further comprises hydroxyethyl cellulose, ethylcellulose, hydroxypropyl cellulose, hypromelloses, or microcrystalline cellulose.
62. The method of claim 34, further comprising subsequently administering to the subject an agent promoting weight loss.
63. The method of claim 62, wherein the agent promoting weight loss is an agent targeting the GLP1 receptor, e.g., semaglutide, liraglutide, danuglipron, or a dual GIP / GLP-1 receptor co-agonist, e.g., tirzepatide, or a dual amylin / GLP-1 receptor coagonist, e.g., amycretin.
64. The method of claim 62, wherein the agent promoting weight loss is an agent inhibiting lipid absorption, e.g., the pancreatic lipase inhibitor, orlistat, or the microsomal transfer protein inhibitor, lomitapide.
65. The method of claim 34, further comprising administering to the subject a CNS stimulant, e.g. lisdexamfetamine dimesylate.
66. The method of claim 34, further comprising administering to the subject topiramate, a selective serotonin reuptake inhibitor (SSRI) or tricyclic antidepressant.
67. The method of claim 34, wherein the therapeutic agent of any of claims 62-66 is administered prior to administration of roflumilast and bupropion.
68. The method of claim 1 or claim 34, wherein the subject is a companion animal such as a dog or cat.
69. The method of claim 68, wherein the companion animal weighing over 2 kg is administered no less than one daily dose of 0.013 mg roflumilast or a pharmaceutically acceptable salt thereof and no less than one daily dose of 4 mg bupropion or a pharmaceutically acceptable salt.
70. The method of claim 68, wherein the companion animal weighing under 70 kg is administered no more than two daily doses of 0.25 mg roflumilast or a pharmaceutically acceptable salt thereof and no more than two daily doses of 75 mg bupropion or a pharmaceutically acceptable salt.
71. Claim 1 or claim 34, wherein the subject has previously been treated with a weight loss promoting agent.
72. The method of claim 71 wherein the weight loss promoting agent is an agent targeting the GLP1 receptor, e.g., semaglutide, liraglutide, danuglipron, or a dual GIP / GLP-1 receptor co-agonist, e.g., tirzepatide, or a dual amylin / GLP-1 receptor coagonist, e.g., amycretin.
73. The method of claim 72, wherein the weight loss promoting agent is an agent inhibiting glucose absorption, or agent inhibiting lipid absorption.
74. The method of claim 1 or claim 34, wherein the subject has previously been treated with a central nervous system agent, selected from the group consisting ofUsdexamfetamine dimesylate, topiramate, a selective serotonin reuptake inhibitor (SSRI) and a tricyclic antidepressant.
75. An article of manufacture comprising a measured amount of one or more of the compositions of claims 1 or 34 and one or more items selected from the group consisting of packaging material, and a package insert comprising instructions for use.
